Efficacy And Safety Of Low-Dose Methotrexate In Generalized And Recalcitrant Lichen Planus: A Retrospective Study At A Tertiary Care Center

被引:0
|
作者
Khurana, Ananta [1 ,2 ]
Sharath, Savitha [1 ,2 ]
Sardana, Kabir [1 ,2 ]
机构
[1] Atal Bihari Vajpayee Inst Med Sci, Dept Dermatol Venereol & Leprosy, Delhi, India
[2] Dr Ram Manohar Lohia Hosp, Delhi, India
来源
DERMATOLOGY PRACTICAL & CONCEPTUAL | 2024年 / 14卷 / 04期
关键词
methotrexate; low-dose; lichen planus; recalcitrant; relapse; adverse effects; THERAPY; PATHWAY;
D O I
10.5826/dpc.1404a220
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Methotrexate (MTX) acts by suppressing multiple immune pathways involved in the pathogenesis of lichen planus (LP). Trials assessing the efficacy and relapse rates of methotrexate in LP are lacking. Objectives: Our objective was to analyze the efficacy and safety of low-dose methotrexate in generalized and recalcitrant LP patients retrospectively and to assess the relapse rates in patients after stopping MTX therapy. Methods: We analyzed clinical and therapeutic details of LP patients treated with low-dose MTX at our center. The cumulative dose and duration of MTX was calculated, and the time to achieve disease control was noted. We analyzed duration of remission and time after which recurrences were seen post-treatment. Results: Records of 42 generalized and recalcitrant LP patients treated with MTX were analyzed. The starting dose of MTX was 7.5 mg (n=7) or 10 mg (n= 35) once weekly, increased to 10/15 mg weekly in patients with inadequate response. Ten patients were lost to follow-up. Complete resolution was achieved in 30/32 (93%) patients within a mean duration of 14.76 weeks (4-32 weeks), and the cumulative dose of MTX to achieve remission was 153.58 mg (50-375 mg). Only minor side effects were noted in 12/32 (37.5%) patients, and none required treatment discontinuation. The mean duration of remission was 29.43 months (5-60 months). Conclusion: MTX demonstrated high efficacy and a good safety profile in extensive cutaneous LP and may be a safer alternative to steroids for this condition.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Study of low-dose tissue plasminogen activator in acute ischemic stroke in a tertiary care center in South India
    Sivan, A.
    Haq, M.
    Ravi, N.
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 : 111 - 111
  • [22] Study of Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in a tertiary Care Center in South India
    Sivan, A.
    Haq, T. P.
    Ravi, N.
    CEREBROVASCULAR DISEASES, 2014, 37 : 347 - 347
  • [23] Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis
    Gabardi, S
    Magee, CC
    Baroletti, SA
    Powelson, JA
    Cina, JL
    Chandraker, AK
    PHARMACOTHERAPY, 2004, 24 (10): : 1323 - 1330
  • [24] Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting
    Chatzimavridou-Grigoriadou, Victoria
    Al-Othman, Sami
    Brabant, Georg
    Kyriacou, Angelos
    King, Jennifer
    Blackhall, Fiona
    Trainer, Peter J.
    Higham, Claire E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (11): : E4766 - E4775
  • [25] The safety and efficacy of laparoscopic cholecystectomy in a tertiary care teaching hospital: A retrospective study
    Mohamud, Abdirahman Ahmed
    Omar, Jafar Abdullahi
    Ahmed, Nur Rashid
    Bashir, Ahmed Muhammad
    JOURNAL OF CLINICAL SCIENCES, 2024, 21 (03) : 113 - 116
  • [26] Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease
    Giaccone, L
    Martin, P
    Carpenter, P
    Moravec, C
    Hooper, H
    Funke, VAM
    Storb, R
    Flowers, MED
    BONE MARROW TRANSPLANTATION, 2005, 36 (04) : 337 - 341
  • [27] Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease
    L Giaccone
    P Martin
    P Carpenter
    C Moravec
    H Hooper
    V A M Funke
    R Storb
    M E D Flowers
    Bone Marrow Transplantation, 2005, 36 : 337 - 341
  • [28] Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study
    Chen, Wei
    Li, Ziting
    Zheng, Zhong
    Wu, Xiaohua
    CANCER MEDICINE, 2020, 9 (16): : 5899 - 5907
  • [29] Safety of Ambulatory High-Dose Methotrexate Administration Among Hematological Malignancies Patients in Tertiary Care Center
    Motabi, Ibraheem
    Albtoosh, Belal
    Alrajhi, Abdullah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S353 - S353
  • [30] Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients
    Pincus, T.
    Furer, V.
    Sokka, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : S68 - S79